Aiolos Bio, a San Francisco, CA-based clinical-stage biopharmaceutical company, raised $245M in Series A funding.
The round was led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments with additional investment from RA Capital Management.
The company intends to use the funds to accelerate development of its lead drug candidate, AIO-001, into a Phase 2 clinical trial in moderate-to-severe asthma patients and is actively evaluating additional development opportunities.
Led by CEO Khurem Farooq, Aiolos Bio helps patients breathe easier whit treatments for respiratory and inflammatory diseases. Its lead drug candidate is AIO-001, a humanized, anti-TSLP mAb in development for moderate-to-severe asthma. AIO-001 is an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody that has the potential to be administered only twice per year due to its differentiated potency and long half-life. TSLP inhibition has a proven role in addressing symptoms of severe asthma and is currently under investigation for additional immune conditions like Chronic Obstructive Pulmonary Disorder (COPD) and Chronic Spontaneous Urticaria (CSU).
Aiolos Bio acquired exclusive rights for global development and commercialization of the drug outside of greater China from Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) in August 2023. In multiple clinical studies, AIO-001 has demonstrated encouraging safety, tolerability, pharmacokinetics, and biological activity in healthy volunteers and asthma patients, with low immunogenicity.
FinSMEs
25/10/2023